JPH0637520B2
(ja)
*
|
1985-07-03 |
1994-05-18 |
味の素株式会社 |
ポリペプチド
|
AU597574B2
(en)
|
1986-03-07 |
1990-06-07 |
Massachusetts Institute Of Technology |
Method for enhancing glycoprotein stability
|
US4973577A
(en)
*
|
1986-04-04 |
1990-11-27 |
The Salk Institute For Biological Studies |
FSH-releasing peptides
|
US5080891A
(en)
|
1987-08-03 |
1992-01-14 |
Ddi Pharmaceuticals, Inc. |
Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
US5198346A
(en)
|
1989-01-06 |
1993-03-30 |
Protein Engineering Corp. |
Generation and selection of novel DNA-binding proteins and polypeptides
|
US5096815A
(en)
|
1989-01-06 |
1992-03-17 |
Protein Engineering Corporation |
Generation and selection of novel dna-binding proteins and polypeptides
|
EP0548276A4
(en)
|
1990-09-13 |
1993-12-29 |
Children's Hospital Medical Center Of Northern California |
Method for increasing red blood cell production by treatment with activin or activin-related peptides
|
US5118667A
(en)
*
|
1991-05-03 |
1992-06-02 |
Celtrix Pharmaceuticals, Inc. |
Bone growth factors and inhibitors of bone resorption for promoting bone formation
|
US6162896A
(en)
*
|
1991-05-10 |
2000-12-19 |
The Salk Institute For Biological Studies |
Recombinant vertebrate activin receptors
|
US5885794A
(en)
*
|
1991-05-10 |
1999-03-23 |
The Salk Institute For Biological Studies |
Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily
|
US20050186593A1
(en)
|
1991-05-10 |
2005-08-25 |
The Salk Institute For Biological Studies |
Cloning and recombinant production of CRF receptor(s)
|
WO1992020793A1
(en)
|
1991-05-10 |
1992-11-26 |
The Salk Institute For Biological Studies |
CLONING AND RECOMBINANT PRODUCTION OF RECEPTOR(S) OF THE ACTIVIN/TGF-β SUPERFAMILY
|
US6287816B1
(en)
|
1991-06-25 |
2001-09-11 |
Genetics Institute, Inc. |
BMP-9 compositions
|
ATE175441T1
(de)
|
1991-06-25 |
1999-01-15 |
Genetics Inst |
Bmp-9 zusammensetzungen
|
WO1993020207A1
(en)
*
|
1992-04-02 |
1993-10-14 |
The United States Of America, As Represented By The Secretary Of Health And Human Services |
Use of restriction endonucleases against viruses, including hiv
|
US6692925B1
(en)
|
1992-11-17 |
2004-02-17 |
Ludwig Institute For Cancer Research |
Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use
|
WO1994015965A1
(en)
|
1993-01-12 |
1994-07-21 |
Johns Hopkins University School Of Medicine |
Growth differentiation factor-3
|
WO1994026893A1
(en)
|
1993-05-12 |
1994-11-24 |
Genetics Institute, Inc. |
Bmp-10 compositions
|
US5637480A
(en)
|
1993-05-12 |
1997-06-10 |
Genetics Institute, Inc. |
DNA molecules encoding bone morphogenetic protein-10
|
US5677196A
(en)
|
1993-05-18 |
1997-10-14 |
University Of Utah Research Foundation |
Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
|
US5831050A
(en)
*
|
1993-06-07 |
1998-11-03 |
Creative Biomolecules, Inc. |
Morphogen cell surface receptor
|
EP0726948B1
(en)
|
1993-10-14 |
2007-02-28 |
President And Fellows Of Harvard College |
Method of inducing and maintaining neuronal cells
|
US5525490A
(en)
|
1994-03-29 |
1996-06-11 |
Onyx Pharmaceuticals, Inc. |
Reverse two-hybrid method
|
US5658876A
(en)
|
1994-04-28 |
1997-08-19 |
The General Hospital Corporation |
Activin antagonists as novel contraceptives
|
AU702163B2
(en)
*
|
1994-04-29 |
1999-02-18 |
Creative Biomolecules, Inc. |
Morphogenic protein-specific cell surface receptors and uses therefor
|
IL114397A0
(en)
*
|
1994-07-01 |
1995-10-31 |
Bioph Biotech Entw Pharm Gmbh |
Growth/differentiation factor of the TGF-beta-family
|
US5760010A
(en)
|
1995-01-01 |
1998-06-02 |
Klein; Ira |
Method of treating liver disorders with a macrolide antibiotic
|
IL117175A
(en)
*
|
1995-02-20 |
2005-11-20 |
Sankyo Co |
Osteoclastogenesis inhibitory factor protein
|
US5814565A
(en)
|
1995-02-23 |
1998-09-29 |
University Of Utah Research Foundation |
Integrated optic waveguide immunosensor
|
AU716893B2
(en)
|
1995-04-11 |
2000-03-09 |
General Hospital Corporation, The |
Reverse two-hybrid systems
|
EP0771873A3
(en)
*
|
1995-10-27 |
1998-03-04 |
Takeda Chemical Industries, Ltd. |
Neuronal cell-specific receptor protein
|
GB9526131D0
(en)
|
1995-12-21 |
1996-02-21 |
Celltech Therapeutics Ltd |
Recombinant chimeric receptors
|
US20050244867A1
(en)
|
1996-03-26 |
2005-11-03 |
Human Genome Sciences, Inc. |
Growth factor HTTER36
|
US6004780A
(en)
|
1996-03-26 |
1999-12-21 |
Human Genome Sciences, Inc. |
Growth factor HTTER36
|
WO1998018926A1
(en)
|
1996-10-25 |
1998-05-07 |
G.D. Searle & Co. |
Circularly permuted erythropoietin receptor agonists
|
US6605699B1
(en)
*
|
1997-01-21 |
2003-08-12 |
Human Genome Sciences, Inc. |
Galectin-11 polypeptides
|
US6034062A
(en)
|
1997-03-13 |
2000-03-07 |
Genetics Institute, Inc. |
Bone morphogenetic protein (BMP)-9 compositions and their uses
|
US6231880B1
(en)
|
1997-05-30 |
2001-05-15 |
Susan P. Perrine |
Compositions and administration of compositions for the treatment of blood disorders
|
US6300127B1
(en)
|
1997-07-30 |
2001-10-09 |
Emory University |
Bone mineralization proteins, DNA, vectors, expression systems
|
US6696260B1
(en)
*
|
1997-08-01 |
2004-02-24 |
The Johns Hopkins University School Of Medicine |
Methods to identify growth differentiation factor (GDF) binding proteins
|
US6891082B2
(en)
|
1997-08-01 |
2005-05-10 |
The Johns Hopkins University School Of Medicine |
Transgenic non-human animals expressing a truncated activintype II receptor
|
AU8666398A
(en)
|
1997-08-01 |
1999-02-22 |
Johns Hopkins University School Of Medicine, The |
Methods to identify growth differentiation factor (gdf) receptors
|
US6656475B1
(en)
*
|
1997-08-01 |
2003-12-02 |
The Johns Hopkins University School Of Medicine |
Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
|
AU8921698A
(en)
|
1997-08-29 |
1999-03-16 |
Human Genome Sciences, Inc. |
Follistatin-3
|
US6953662B2
(en)
*
|
1997-08-29 |
2005-10-11 |
Human Genome Sciences, Inc. |
Follistatin-3
|
ATE373712T1
(de)
|
1997-10-03 |
2007-10-15 |
Chugai Pharmaceutical Co Ltd |
Natürlicher menschlicher antikörper
|
US6696411B1
(en)
|
1998-04-22 |
2004-02-24 |
Cornell Research Foundation, Inc. |
Canine erythropoietin gene and recombinant protein
|
WO1999065948A1
(en)
|
1998-06-16 |
1999-12-23 |
Biogen, Inc. |
Variant type ii tgf-beta receptor fusion proteins and methods
|
JP2002524514A
(ja)
*
|
1998-09-17 |
2002-08-06 |
イーライ・リリー・アンド・カンパニー |
タンパク質製剤
|
DE69934995T2
(de)
|
1998-09-22 |
2007-11-22 |
Long Yu |
Für den menschlichen wachstums-differenzierungsfaktor kodierende sequenz und polypeptid, welches durch solche dna-sequenz kodiert wird und verfahren zur herstellung
|
US6472179B2
(en)
*
|
1998-09-25 |
2002-10-29 |
Regeneron Pharmaceuticals, Inc. |
Receptor based antagonists and methods of making and using
|
US6548634B1
(en)
|
1998-09-30 |
2003-04-15 |
Chiron Corporation |
Synthetic peptides having FGF receptor affinity
|
US6238860B1
(en)
|
1998-11-05 |
2001-05-29 |
Dyax Corp. |
Binding moieties for human parvovirus B19
|
US6777205B1
(en)
|
1998-11-06 |
2004-08-17 |
Sterrenbeld Biotechnologie North America, Inc. |
Host cells expressing recombinant human erythropoietin
|
US20040009535A1
(en)
|
1998-11-27 |
2004-01-15 |
Celltech R&D, Inc. |
Compositions and methods for increasing bone mineralization
|
NZ512122A
(en)
*
|
1998-11-27 |
2003-12-19 |
Darwin Discovery Ltd |
Compositions and methods for increasing bone mineralization
|
NZ513642A
(en)
|
1999-01-21 |
2004-02-27 |
Metamorphix Inc |
Growth differentiation factor inhibitors and uses therefor
|
US6914128B1
(en)
|
1999-03-25 |
2005-07-05 |
Abbott Gmbh & Co. Kg |
Human antibodies that bind human IL-12 and methods for producing
|
WO2000062809A1
(fr)
|
1999-04-19 |
2000-10-26 |
Kyowa Hakko Kogyo Co., Ltd. |
Inhibiteur de proliferation cellulaire pour tumeurs androgeno-independantes
|
US6468543B1
(en)
|
1999-05-03 |
2002-10-22 |
Zymogenetics, Inc. |
Methods for promoting growth of bone using ZVEGF4
|
BR0015506A
(pt)
|
1999-11-12 |
2002-07-23 |
Maxygen Holdings Ltd |
Conjugados de interferon gama, métodos para sua preparação, composições farmacêuticas que compreendem ás moléculas e seu uso no tratamento de doenças
|
WO2001043763A1
(en)
|
1999-12-15 |
2001-06-21 |
Research Development Foundation |
Betaglycan as an inhibin receptor and uses thereof
|
US20030224501A1
(en)
|
2000-03-17 |
2003-12-04 |
Young Paul E. |
Bone morphogenic protein polynucleotides, polypeptides, and antibodies
|
JP4487376B2
(ja)
*
|
2000-03-31 |
2010-06-23 |
味の素株式会社 |
腎疾患治療剤
|
PT1311285E
(pt)
|
2000-05-15 |
2005-06-30 |
Hoffmann La Roche |
Composicao farmaceutica liquida contendo um derivado de eritropoietina
|
US6627424B1
(en)
|
2000-05-26 |
2003-09-30 |
Mj Bioworks, Inc. |
Nucleic acid modifying enzymes
|
US20030215913A1
(en)
|
2000-07-19 |
2003-11-20 |
Enrique Alvarez |
Nucleic acids, vectors, host cells, polypeptides, and uses thereof
|
US6632180B1
(en)
|
2000-09-07 |
2003-10-14 |
John H. Laragh |
Method for evaluating and treating hypertension
|
DE10045591A1
(de)
|
2000-09-15 |
2002-04-04 |
Klaus Pfizenmaier |
Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine)
|
JP2004526419A
(ja)
|
2000-10-16 |
2004-09-02 |
フィロス インク. |
抗体模倣物および他の結合タンパク質のためのタンパク質骨格
|
US7087224B2
(en)
|
2000-10-31 |
2006-08-08 |
Amgen Inc. |
Method of treating anemia by administering IL-1ra
|
EP1345959B1
(en)
|
2000-11-20 |
2011-05-25 |
The Board Of Trustees Of The University Of Illinois |
Membrane scaffold proteins
|
WO2002043759A2
(en)
|
2000-12-01 |
2002-06-06 |
Wyeth |
Method and composition for modulating bone growth
|
US20030082233A1
(en)
|
2000-12-01 |
2003-05-01 |
Lyons Karen M. |
Method and composition for modulating bone growth
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
TWI329129B
(en)
*
|
2001-02-08 |
2010-08-21 |
Wyeth Corp |
Modified and stabilized gdf propeptides and uses thereof
|
US20040132971A1
(en)
*
|
2001-02-09 |
2004-07-08 |
Haaning Jesper Mortensen |
Rank ligand-binding polypeptides
|
US20040132675A1
(en)
|
2002-02-08 |
2004-07-08 |
Calvin Kuo |
Method for treating cancer and increasing hematocrit levels
|
US7294472B2
(en)
*
|
2001-03-14 |
2007-11-13 |
Caden Biosciences |
Method for identifying modulators of G protein coupled receptor signaling
|
US20040121008A1
(en)
|
2001-03-16 |
2004-06-24 |
Keiko Shiraishi |
Process for producing sustained release preparation
|
ATE472609T1
(de)
|
2001-04-26 |
2010-07-15 |
Amgen Mountain View Inc |
Kombinatorische bibliotheken von monomerdomänen
|
RS52228B
(sr)
|
2001-05-24 |
2012-10-31 |
Zymogenetics, Inc. |
Taci-imunoglobulinski fuzioni proteini
|
WO2002094864A2
(en)
|
2001-05-25 |
2002-11-28 |
Genset S.A. |
Human cdnas and proteins and uses thereof
|
AUPR638101A0
(en)
|
2001-07-13 |
2001-08-09 |
Bioa Pty Limited |
Composition and method for treatment of disease
|
US6855344B2
(en)
*
|
2001-07-17 |
2005-02-15 |
Integrated Chinese Medicine Holdings, Ltd. |
Compositions and methods for prostate and kidney health and disorders, an herbal preparation
|
US7396642B2
(en)
|
2001-07-17 |
2008-07-08 |
Teijin Limited |
Methods of screening for a compound that enhances thermogenesis
|
KR100453877B1
(ko)
|
2001-07-26 |
2004-10-20 |
메덱스젠 주식회사 |
연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 TNFR/Fc 융합 단백질, 상기 단백질을 코딩하는 DNA, 상기 DNA를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
|
US7320789B2
(en)
|
2001-09-26 |
2008-01-22 |
Wyeth |
Antibody inhibitors of GDF-8 and uses thereof
|
US6784154B2
(en)
|
2001-11-01 |
2004-08-31 |
University Of Utah Research Foundation |
Method of use of erythropoietin to treat ischemic acute renal failure
|
CN102552262A
(zh)
|
2001-12-06 |
2012-07-11 |
法布罗根股份有限公司 |
提高内源性红细胞生成素(epo)的方法
|
US20060234918A1
(en)
|
2001-12-19 |
2006-10-19 |
Voyager Pharmaceutical Corporation |
Methods for treating and preventing cancers that express the hypothalamic-pituitary-gonadal axis of hormones and receptors
|
US20030144203A1
(en)
|
2001-12-19 |
2003-07-31 |
Voyager Pharmaceutical Corporation |
Methods for slowing senescence and treating and preventing diseases associated with senescence
|
US6998118B2
(en)
|
2001-12-21 |
2006-02-14 |
The Salk Institute For Biological Studies |
Targeted retrograde gene delivery for neuronal protection
|
AU2003216250A1
(en)
|
2002-02-11 |
2003-09-04 |
Genentech, Inc. |
Antibody variants with faster antigen association rates
|
AU2003217612A1
(en)
|
2002-02-21 |
2003-09-09 |
Wyeth |
GASP1: a follistatin domain containing protein
|
US20030219846A1
(en)
|
2002-02-28 |
2003-11-27 |
Pfizer Inc. |
Assay for activity of the ActRIIB kinase
|
US8053552B2
(en)
*
|
2002-04-18 |
2011-11-08 |
Mtm Laboratories, Ag |
Neopeptides and methods useful for detection and treatment of cancer
|
DE10234192B4
(de)
|
2002-07-26 |
2009-11-26 |
Epoplus Gmbh Co.Kg |
Verwendung von Erythropoetin
|
MXPA05001694A
(es)
|
2002-08-16 |
2005-07-22 |
Wyeth Corp |
Elementos de respuesta al estrogeno de bmp-2 y metodos de uso de los mismos.
|
US7261893B2
(en)
|
2002-10-22 |
2007-08-28 |
Wyeth |
Neutralizing antibodies against GDF-8 and uses therefor
|
US20040223966A1
(en)
*
|
2002-10-25 |
2004-11-11 |
Wolfman Neil M. |
ActRIIB fusion polypeptides and uses therefor
|
AU2002953327A0
(en)
|
2002-12-12 |
2003-01-09 |
Monash University |
Methods of diagnosing prognosing and treating activin associated diseases and conditions
|
DE602004018902D1
(de)
|
2003-02-07 |
2009-02-26 |
Prometic Biosciences Inc |
Fettsäuren mittlerer kettenlänge, glyceride und analoga als stimulatoren der erythropoiese
|
WO2004086953A2
(en)
|
2003-03-26 |
2004-10-14 |
The Board Of Trustees Of The University Of Arkansas |
Method for diagnosis and treatment of bone turnover
|
US20070184052A1
(en)
*
|
2003-05-09 |
2007-08-09 |
Lin Herbert Y |
Soluble tgf-b type III receptor fusion proteins
|
CN1829532A
(zh)
|
2003-06-02 |
2006-09-06 |
惠氏公司 |
肌肉抑制素(gdf8)抑制剂和皮质类固醇联合用于治疗神经肌肉紊乱的用途
|
BRPI0411552A
(pt)
|
2003-06-16 |
2006-08-01 |
Celltech R & D Inc |
anticorpos especìficos a esclerostina e métodos para aumentar a mineralização óssea
|
WO2005009460A2
(en)
|
2003-07-25 |
2005-02-03 |
Medexis, S.A. |
Pharmaceutical composition comprising activin a, alk-4 or derivatives thereof for the treatment of ophthalmic disorders or cancer
|
US8895540B2
(en)
|
2003-11-26 |
2014-11-25 |
DePuy Synthes Products, LLC |
Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
|
EP1706428B1
(en)
*
|
2004-01-22 |
2009-09-23 |
MERCK PATENT GmbH |
Anti-cancer antibodies with reduced complement fixation
|
US20050197292A1
(en)
*
|
2004-01-30 |
2005-09-08 |
Glennda Smithson |
Compositions and methods for treating T-cell mediated pathological conditions
|
CA2561317A1
(en)
*
|
2004-03-26 |
2005-10-13 |
Acceleron Pharma Inc. |
Bmp-3 propeptides and related methods
|
US7459527B2
(en)
|
2004-03-31 |
2008-12-02 |
Xencor, Inc. |
BMP-7 variants with improved properties
|
WO2005113590A2
(en)
|
2004-05-12 |
2005-12-01 |
Acceleron Pharma Inc. |
Bmp10 propeptides and related methods
|
AU2005258286A1
(en)
|
2004-06-24 |
2006-01-05 |
Acceleron Pharma Inc. |
GDF3 propeptides and related methods
|
ES2426005T3
(es)
|
2004-07-23 |
2013-10-18 |
Acceleron Pharma Inc. |
Polipéptidos del receptor ACTRII, procedimientos y composiciones
|
WO2006015368A2
(en)
|
2004-08-05 |
2006-02-09 |
The Regents Of The University Of California |
Molecules with effects on cellular development and function
|
CA2575563A1
(en)
|
2004-08-12 |
2006-02-23 |
Wyeth |
Combination therapy for diabetes, obesity, and cardiovascular diseases using gdf-8 inhibitors
|
CA2581896C
(en)
|
2004-09-29 |
2015-11-10 |
Mount Sinai School Of Medicine Of New York University |
Fsh and fsh receptor modulator compositions and methods for inhibiting osteoclastic bone resorption and bone loss in osteoporosis
|
WO2006055689A2
(en)
|
2004-11-16 |
2006-05-26 |
Avidia Research Institute |
Protein scaffolds and uses thereof
|
NL1027887C2
(nl)
|
2004-12-24 |
2006-06-27 |
Bosch Gmbh Robert |
Transmissie met gebombeerde poelieschijven en een drijfriem.
|
NZ538097A
(en)
|
2005-02-07 |
2006-07-28 |
Ovita Ltd |
Method and compositions for improving wound healing
|
EP1858541B1
(en)
|
2005-02-16 |
2012-07-25 |
The General Hospital Corporation |
Use of bmp antagonists to regulate hepcidin-mediated iron metabolism and treat iron deficiency
|
KR20080011403A
(ko)
|
2005-04-25 |
2008-02-04 |
화이자 인크. |
미오스타틴에 대한 항체
|
CN101198321A
(zh)
|
2005-04-26 |
2008-06-11 |
味之素株式会社 |
骨髓祖红细胞分化诱导剂
|
JP2007099764A
(ja)
|
2005-09-09 |
2007-04-19 |
Ajinomoto Co Inc |
血糖低下剤
|
WO2007038703A2
(en)
|
2005-09-28 |
2007-04-05 |
Zymogenetics, Inc |
Il-17a and il-17f antagonists and methods of using the same
|
US8067562B2
(en)
|
2005-11-01 |
2011-11-29 |
Amgen Inc. |
Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
|
US8128933B2
(en)
|
2005-11-23 |
2012-03-06 |
Acceleron Pharma, Inc. |
Method of promoting bone growth by an anti-activin B antibody
|
EA015105B1
(ru)
*
|
2005-11-23 |
2011-06-30 |
Акселерон Фарма Инк. |
Антагонисты активина - actriia и их применение для стимулирования роста кости
|
CA2632544C
(en)
|
2005-12-06 |
2014-09-23 |
Amgen Inc. |
Use of myostatin antagonist for treating the effects of hypogonadism
|
CA2632936A1
(en)
|
2005-12-20 |
2007-06-28 |
Merck Frosst Canada Ltd. |
Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
|
US20070161578A1
(en)
|
2005-12-21 |
2007-07-12 |
Hwa Joyce J |
Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or H3 receptor antagonist/inverse agonist
|
WO2007076127A2
(en)
|
2005-12-22 |
2007-07-05 |
Biogen Idec Ma Inc |
Condensed imidazoles or pyrazoles and their use as transforming growth factor modulators
|
WO2007084977A2
(en)
*
|
2006-01-20 |
2007-07-26 |
Beckman Coulter, Inc. |
Low hemoglobin concentration cell percentage and method of use in detection of iron deficiency
|
EP1976377A4
(en)
|
2006-01-25 |
2010-06-23 |
Wellstat Therapeutics Corp |
COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
|
KR20080098615A
(ko)
|
2006-02-28 |
2008-11-11 |
웰스태트 테러퓨틱스 코포레이션 |
물질대사 장애의 치료용 화합물
|
CA2650131A1
(en)
|
2006-04-14 |
2007-10-25 |
Amgen Inc. |
Agonist erythropoietin receptor antibodies
|
WO2007123391A1
(en)
|
2006-04-20 |
2007-11-01 |
Academisch Ziekenhuis Leiden |
Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene.
|
EP2023913A2
(en)
*
|
2006-05-09 |
2009-02-18 |
Colorado State University Research Foundation |
Methods for treating blood disorders
|
TW200803123A
(en)
*
|
2006-06-02 |
2008-01-01 |
Delta Electronics Inc |
Power converter and magnetic structure thereof
|
AU2007275606B9
(en)
*
|
2006-07-21 |
2013-09-26 |
Lyne Laboratories, Inc. |
Liquid compositions of calcium acetate
|
GB0615129D0
(en)
|
2006-07-29 |
2006-09-06 |
Univ Cardiff |
Anti-cancer activity of BMP-9 and BMP-10 and their use in cancer therapies
|
CL2007002567A1
(es)
|
2006-09-08 |
2008-02-01 |
Amgen Inc |
Proteinas aisladas de enlace a activina a humana.
|
US7547781B2
(en)
|
2006-09-11 |
2009-06-16 |
Curis, Inc. |
Quinazoline based EGFR inhibitors containing a zinc binding moiety
|
WO2008060139A1
(en)
|
2006-11-17 |
2008-05-22 |
Erasmus University Medical Center Rotterdam |
Methods for controlling mineralization of extracellular matrix, therapeutic methods based thereon and medicaments for use therein
|
US20100003190A1
(en)
|
2006-12-08 |
2010-01-07 |
Caritas St. Elizabeth's Medical Center Of Boston, Inc. |
Method for protecting renal tubular epithelial cells from radiocontrast nephropathy (RCN)
|
US20100111852A1
(en)
|
2006-12-14 |
2010-05-06 |
Forerunner Pharma Research Co., Ltd. |
Anti-Claudin 3 Monoclonal Antibody and Treatment and Diagnosis of Cancer Using the Same
|
US8895016B2
(en)
|
2006-12-18 |
2014-11-25 |
Acceleron Pharma, Inc. |
Antagonists of activin-actriia and uses for increasing red blood cell levels
|
US20100028332A1
(en)
|
2006-12-18 |
2010-02-04 |
Acceleron Pharma Inc. |
Antagonists of actriib and uses for increasing red blood cell levels
|
CN105582521A
(zh)
*
|
2006-12-18 |
2016-05-18 |
阿塞勒隆制药公司 |
活化素-actrii拮抗剂及在提高红细胞水平中的用途
|
TR200906131T1
(tr)
*
|
2007-02-01 |
2009-11-23 |
Acceleron Pharma Inc. |
Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e
|
TW201940502A
(zh)
|
2007-02-02 |
2019-10-16 |
美商艾瑟勒朗法瑪公司 |
衍生自ActRIIB的變體與其用途
|
ES2394123T3
(es)
*
|
2007-02-09 |
2013-01-22 |
Acceleron Pharma, Inc. |
Composiciones farmacéuticas que comprenden antagonistas de Activina-Actrlla y uso de las mismas en la prevención o el tratamiento de mieloma múltiple
|
US7947646B2
(en)
|
2007-03-06 |
2011-05-24 |
Amgen Inc. |
Variant activin receptor polypeptides
|
US8501678B2
(en)
|
2007-03-06 |
2013-08-06 |
Atara Biotherapeutics, Inc. |
Variant activin receptor polypeptides and uses thereof
|
WO2008151078A1
(en)
|
2007-06-01 |
2008-12-11 |
Wyeth |
Methods and compositions for modulating bmp-10 activity
|
WO2009009059A1
(en)
|
2007-07-09 |
2009-01-15 |
Biogen Idec Ma Inc. |
Spiro compounds as antagonists of tgf-beta
|
US20090025308A1
(en)
*
|
2007-07-26 |
2009-01-29 |
Deans Brian W |
Seismic support and reinforcement systems
|
ES2617957T3
(es)
|
2007-08-03 |
2017-06-20 |
Summit (Oxford) Limited |
Combinaciones farmacológicas para el tratamiento de la distrofia muscular de Duchenne
|
GB0715087D0
(en)
|
2007-08-03 |
2007-09-12 |
Summit Corp Plc |
Drug combinations for the treatment of duchenne muscular dystrophy
|
GB0715938D0
(en)
|
2007-08-15 |
2007-09-26 |
Vastox Plc |
Method of treatment of duchenne muscular dystrophy
|
WO2009025651A1
(en)
|
2007-08-17 |
2009-02-26 |
University Of Maine System Board Of Trustees |
Biologically active peptide and method of using the same
|
WO2009035629A1
(en)
|
2007-09-13 |
2009-03-19 |
Ludwig Institute Of Cancer Research |
Method for modifying cellular immune response by modulating activin activity
|
CN101861161B
(zh)
|
2007-09-18 |
2017-04-19 |
阿塞勒隆制药公司 |
活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
|
PE20091163A1
(es)
|
2007-11-01 |
2009-08-09 |
Wyeth Corp |
Anticuerpos para gdf8
|
WO2009070243A2
(en)
|
2007-11-21 |
2009-06-04 |
Amgen Inc. |
Wise binding agents and epitopes
|
US8507501B2
(en)
|
2008-03-13 |
2013-08-13 |
The Brigham And Women's Hospital, Inc. |
Inhibitors of the BMP signaling pathway
|
US20110104133A1
(en)
|
2008-05-06 |
2011-05-05 |
Joslin Diabetes Center, Inc. |
Methods and compositions for inducing brown adipogenesis
|
WO2009137075A1
(en)
*
|
2008-05-06 |
2009-11-12 |
Acceleron Pharma Inc. |
Anti-activin antibodies and uses for promoting bone growth
|
WO2009158035A2
(en)
|
2008-06-26 |
2009-12-30 |
Acceleron Pharma Inc. |
Methods for dosing an activin-actriia antagonist and monitoring of treated patients
|
EP2318028B1
(en)
|
2008-06-26 |
2020-02-19 |
Acceleron Pharma Inc. |
Antagonists of soluble activin-actriia and uses for increasing red blood cell levels
|
WO2010019261A1
(en)
|
2008-08-14 |
2010-02-18 |
Acceleron Pharma Inc. |
Use of gdf traps to increase red blood cell levels
|
US8216997B2
(en)
|
2008-08-14 |
2012-07-10 |
Acceleron Pharma, Inc. |
Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
|
US20110293526A1
(en)
|
2008-11-20 |
2011-12-01 |
University Of Southern California |
Compositions and methods to modulate hair growth
|
KR101720143B1
(ko)
|
2008-11-26 |
2017-03-27 |
암젠 인크 |
액티빈 iib 수용체 폴리펩타이드의 변이체 및 이의 용도
|
AU2010204985A1
(en)
|
2009-01-13 |
2011-08-04 |
Acceleron Pharma Inc. |
Methods for increasing adiponectin
|
US8110355B2
(en)
|
2009-02-20 |
2012-02-07 |
GenRemedy, LLC |
Methods for identifying agents that inhibit cell migration, promote cell adhesion and prevent metastasis
|
NO2424895T3
(sr)
|
2009-04-27 |
2018-02-03 |
|
|
CN104840944A
(zh)
|
2009-06-08 |
2015-08-19 |
阿塞勒隆制药公司 |
用于增加产热脂肪细胞的方法
|
EP2440577A4
(en)
|
2009-06-12 |
2013-01-23 |
Acceleron Pharma Inc |
SHORTEN ACTRIIB FC FUSION PROTEINS
|
NZ712943A
(en)
|
2009-08-13 |
2017-08-25 |
Acceleron Pharma Inc |
Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
|
KR20200086378A
(ko)
|
2009-09-09 |
2020-07-16 |
악셀레론 파마 인코포레이티드 |
ActRIIb 길항제들와 이의 투약 및 용도
|
AU2010315245B2
(en)
|
2009-11-03 |
2016-11-03 |
Acceleron Pharma Inc. |
Methods for treating fatty liver disease
|
AU2010322011B2
(en)
|
2009-11-17 |
2016-03-31 |
Acceleron Pharma Inc. |
ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
|
WO2012027065A2
(en)
|
2010-08-27 |
2012-03-01 |
Celgene Corporation |
Combination therapy for treatment of disease
|
US8580922B2
(en)
|
2011-03-04 |
2013-11-12 |
Shire Human Genetic Therapies, Inc. |
Peptide linkers for polypeptide compositions and methods for using same
|
US9365651B2
(en)
|
2011-07-01 |
2016-06-14 |
Novartis Ag |
Method for treating metabolic disorders by administration of an anti-ActRIIB antibody
|
EP2797620B1
(en)
|
2011-10-17 |
2019-04-24 |
Acceleron Pharma Inc. |
Compositions for treating iron overload in thalassemia
|
US8765385B2
(en)
|
2011-10-27 |
2014-07-01 |
Ravindra Kumar |
Method of detection of neutralizing anti-actriib antibodies
|
WO2013063536A1
(en)
|
2011-10-27 |
2013-05-02 |
Acceleron Pharma, Inc. |
Actriib binding agents and uses thereof
|
BR112014009949A8
(pt)
|
2011-10-28 |
2018-01-16 |
Paranta Biosciences Ltd |
métodos de tratamento de hipersecreção de muco e uso de agentes
|
CN104379159A
(zh)
|
2011-12-19 |
2015-02-25 |
安姆根公司 |
变体激活素受体多肽,单独或与化疗结合,及其用途
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
US9663569B2
(en)
|
2012-06-14 |
2017-05-30 |
The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center |
Use of blocking agents of bone morphogenic protein (BMP) signalling for the treatment of neuroinflammatory and neurodegenerative diseases
|
WO2014007198A1
(ja)
|
2012-07-02 |
2014-01-09 |
協和発酵キリン株式会社 |
抗bmp9抗体を有効成分とする、腎性貧血、がん性貧血などの貧血に対する治療剤
|
CA2889286A1
(en)
|
2012-10-24 |
2014-05-01 |
Celgene Corporation |
Methods for treating anemia
|
ES2753811T3
(es)
|
2012-10-24 |
2020-04-14 |
Celgene Corp |
Biomarcador para uso en el tratamiento de anemia
|
WO2014064292A1
(en)
|
2012-10-26 |
2014-05-01 |
Universite Pierre Et Marie Curie (Paris 6) |
A method for preventing or treating atrial fibrillation
|
ES2652437T3
(es)
|
2012-11-02 |
2018-02-02 |
Celgene Corporation |
Antagonistas de activina-actrii y usos para el tratamiento de trastornos óseos y otros trastornos
|
ES2813869T3
(es)
|
2012-11-08 |
2021-03-25 |
Clearside Biomedical Inc |
Métodos para el tratamiento de la enfermedad ocular en sujetos humanos
|
WO2014093531A1
(en)
|
2012-12-11 |
2014-06-19 |
Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center |
Modulation of myofiber repair by anti-myostatin in strategies with stem cells
|
US20140220033A1
(en)
|
2013-02-01 |
2014-08-07 |
Santa Maria Biotherapeutics, Inc. |
Administration of an Anti-Activin-A Compound to a Subject
|
EP2970940B1
(en)
|
2013-03-14 |
2018-07-25 |
Translate Bio, Inc. |
Mrna therapeutic compositions and use to treat diseases and disorders
|
TW201920262A
(zh)
|
2013-07-30 |
2019-06-01 |
美商再生元醫藥公司 |
抗活化素a之抗體及其用途
|
KR20160042987A
(ko)
|
2013-08-14 |
2016-04-20 |
노파르티스 아게 |
산발성 봉입체 근염을 치료하는 방법
|
JP2017505428A
(ja)
|
2013-12-16 |
2017-02-16 |
パランタ バイオサイエンス リミテッド |
診断及び治療の方法
|
EP3094751A4
(en)
|
2014-01-14 |
2017-06-07 |
Santa Maria Biotherapeutics, Inc. |
Activin inhibitor response prediction and uses for treatment
|
CN105992951A
(zh)
|
2014-01-27 |
2016-10-05 |
诺华股份有限公司 |
预测肌萎缩的生物标志物、方法和用途
|
US10260068B2
(en)
|
2014-03-31 |
2019-04-16 |
Sumitomo Dainippon Pharma Co., Ltd. |
Prophylactic agent and therapeutic agent for fibrodysplasia ossificans progressiva
|
CA2962197C
(en)
|
2014-04-18 |
2023-10-03 |
Ravindra Kumar |
Methods for increasing red blood cell levels and treating sickle-cell disease
|
TW201622746A
(zh)
|
2014-04-24 |
2016-07-01 |
諾華公司 |
改善或加速髖部骨折術後身體復原之方法
|
MA51075A
(fr)
|
2014-06-04 |
2020-10-14 |
Acceleron Pharma Inc |
Procédés et compositions pour traiter des troubles à l'aide de polypeptides de follistatine
|
BR112016029211A2
(pt)
|
2014-06-13 |
2018-01-30 |
Amgen Inc |
composição, método para inibir um crescimento tumoral sólido em um indivíduo, método para produzir uma proteína, método para inibir, reduzir ou tratar de caquexia em um indivíduo, método para tratar obesidade ou uma doença associada à obesidade e kit
|
CN107847562A
(zh)
|
2015-05-13 |
2018-03-27 |
细胞基因公司 |
使用 ACTRII 配体陷阱治疗 β‑地中海贫血
|